Search for a command to run...
Objectives Cenerimod is an investigational highly selective S1PR1 receptor modulator with potential therapeutic benefits in autoimmune disease, including Systemic Lupus Erythematous (SLE).The Phase 2b CARE study was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of different doses of cenerimod (05 mg, 1 mg, 2 mg, or 4mg) in subjects with moderate-to-severe SLE, concurrently receiving stable background therapy.The CARE study also assessed health-related quality of life (QoL) as one of its endpoints, and the abstract presents the QoL results comparing cenerimod 4 mg to placebo.Methods The 36-Item Short Form Health Survey version 2 (SF-36v2) was one of the tools used to assess quality of life (QoL) in the CARE study.The data was collected using a paper clinical report form (CRF). Observed changes from baseline to month 6 were analyzed descriptively using the full analysis set.Results Improvements were noted with cenerimod 4 mg vs placebo at month 6 across most of the SF-36v2 health domains.The mean [SD] change from baseline to month 6 with 4 mg was 4.72 [8.17] for the physical component summary (vs placebo, 2.60 [9.91]) and 2. 73 [8.99] for the mental component summary (vs placebo, 2.51 [11.74]).In the subgroup of patients with high IFN-1 gene expression, the treatment effect was greater with a mean [SD] changes higher for 4 mg vs placebo in both physical (6.77 [7.80] vs 0.99 [9.81]) and mental components (3.14 [10.25] vs 0.75 [13.39]).For the SF-36 mental health domain at month 6, the mean [SD] difference was 3.02 with 4 mg vs 2.63 for placebo.In the high IFN-1 gene expression subgroup, the mean difference was 2.82 [9.76] for the 4 mg vs -0.07 [12.10] for the placebo.Conclusions Patients with cenerimod 4 mg groups showed meaning full improvements in the mental and physical components of the SF-36v2 scores compared to placebo at month 6.Further evaluation of the SF-36v2 scores will be performed in the phase III program.